On the public citation graph

Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials

https://doi.org/10.1136/bmjopen-2014-005442
0 signed · 95 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/archinternmed.2011.4openalex-snapshot
When Metformin Fails in Type 2 Diabetes Mellitus
inferredcites →https://doi.org/10.1001/jama.2010.405openalex-snapshot
Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes
inferredcites →https://doi.org/10.1002/9780470693926openalex-snapshot
Systematic Reviews in Health Care
inferredcites →https://doi.org/10.1002/9780470693926.ch15openalex-snapshot
Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta‐Analysis
inferredcites →https://doi.org/10.1002/9780470712184.ch8openalex-snapshot
Assessing Risk of Bias in Included Studies
inferredcites →https://doi.org/10.1007/s12020-013-0090-0openalex-snapshot
Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors
inferredcites →https://doi.org/10.1007/s12020-013-9918-xopenalex-snapshot
Does personalized diabetology overcome clinical uncertainty and therapeutic inertia in type 2 diabetes?
inferredcites →https://doi.org/10.1016/s0140-6736(12)60691-6openalex-snapshot
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
inferredcites →https://doi.org/10.1055/s-0028-1082334openalex-snapshot
Efficacy and Safety of Vildagliptin Monotherapy during 2-Year Treatment of Drug-naïve Patients with Type 2 Diabetes: Comparison with Metformin
inferredcites →https://doi.org/10.1055/s-0029-1234042openalex-snapshot
Efficacy and Safety Comparison Between the DPP-4 Inhibitor Vildagliptin and the Sulfonylurea Gliclazide After Two Years of Monotherapy in Drug-naïve Patients with Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa066224openalex-snapshot
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
inferredcites →https://doi.org/10.1056/nejmoa1305889openalex-snapshot
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1307684openalex-snapshot
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
inferredcites →https://doi.org/10.1111/ijcp.12119openalex-snapshot
Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial
inferredcites →https://doi.org/10.1111/j.1463-1326.2007.00835.xopenalex-snapshot
Robust improvements in fasting and prandial measures of β‐cell function with vildagliptin in drug‐naïve patients: analysis of pooled vildagliptin monotherapy database
inferredcites →https://doi.org/10.1111/j.1463-1326.2008.01021.xopenalex-snapshot
Long‐term 2‐year safety and efficacy of vildagliptin compared with rosiglitazone in drug‐naïve patients with type 2 diabetes mellitus
inferredcites →https://doi.org/10.1111/j.1463-1326.2010.01204.xopenalex-snapshot
Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes
inferredcites →https://doi.org/10.1111/j.1463-1326.2010.01233.xopenalex-snapshot
Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study
inferredcites →https://doi.org/10.1111/j.1463-1326.2011.01385.xopenalex-snapshot
Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks
inferredcites →https://doi.org/10.1111/j.1742-1241.2010.02353.xopenalex-snapshot
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
inferredcites →https://doi.org/10.1177/1479164111404574openalex-snapshot
Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks
inferredcites →https://doi.org/10.1177/1479164111404575openalex-snapshot
Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus
inferredcites →https://doi.org/10.1371/journal.pmed.1000100openalex-snapshot
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
inferredcites →https://doi.org/10.2337/db05-1602openalex-snapshot
Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes
inferredcites →https://doi.org/10.2337/dc13-0356openalex-snapshot
Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
inferredcites →https://doi.org/10.2337/dc13-0663openalex-snapshot
Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin
inferredcites →https://doi.org/10.2337/dc13-2097openalex-snapshot
Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012
inferredcites →https://doi.org/10.7326/0003-4819-151-4-200908180-00136openalex-snapshot
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4657441openalex-extracted
Cardiovascular Events and Heart Failure in Patients with Type 2 Diabetes Treated with Dipeptidyl Peptidase-4 Inhibitors: An Update Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1002/dmrr.2981openalex-snapshot
When metformin is not enough: Pros and cons of SGLT2 and DPP‐4 inhibitors as a second line therapy
inferred← citeshttps://doi.org/10.1002/edm2.100openalex-snapshot
Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1002/edm2.371openalex-snapshot
Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity
inferred← citeshttps://doi.org/10.1007/978-3-030-18899-3_19openalex-snapshot
Drugs for Treatment of Diabetes Mellitus
inferred← citeshttps://doi.org/10.1007/s00125-018-4729-5openalex-snapshot
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
inferred← citeshttps://doi.org/10.1007/s00592-018-1164-5openalex-snapshot
DPP-4 inhibitors for the treatment of type 2 diabetes: a methodology overview of systematic reviews
inferred← citeshttps://doi.org/10.1007/s00592-018-1222-zopenalex-snapshot
The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials
inferred← citeshttps://doi.org/10.1007/s00592-018-1271-3openalex-snapshot
Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.1007/s11136-024-03753-6openalex-snapshot
The impact of dipeptidyl peptidase 4 inhibitors on health-related quality of life in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s11892-017-0828-9openalex-snapshot
Medical Management of Diabesity: Do We Have Realistic Targets?
inferred← citeshttps://doi.org/10.1007/s13300-016-0172-0openalex-snapshot
Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment
inferred← citeshttps://doi.org/10.1007/s13300-018-0372-xopenalex-snapshot
Efficacy and Safety of Teneligliptin 40 mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies
inferred← citeshttps://doi.org/10.1007/s13300-019-00733-9openalex-snapshot
Management of Type 2 Diabetes in Developing Countries: Balancing Optimal Glycaemic Control and Outcomes with Affordability and Accessibility to Treatment
inferred← citeshttps://doi.org/10.1007/s13300-021-01148-1openalex-snapshot
Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study
inferred← citeshttps://doi.org/10.1007/s40273-015-0266-yopenalex-snapshot
Cost Effectiveness of Dipeptidyl Peptidase-4 Inhibitors for Type 2 Diabetes
inferred← citeshttps://doi.org/10.1016/j.bioorg.2020.103810openalex-snapshot
Drug discovery approaches targeting the incretin pathway
inferred← citeshttps://doi.org/10.1016/j.biopha.2023.114561openalex-snapshot
Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome
inferred← citeshttps://doi.org/10.1016/j.curtheres.2025.100804openalex-snapshot
Cardiovascular Events and Heart Failure in Patients With Type 2 Diabetes Treated With Dipeptidyl Peptidase-4 Inhibitors: A Meta-Analysis
inferred← citeshttps://doi.org/10.1016/j.diabres.2018.05.028openalex-snapshot
The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents
inferred← citeshttps://doi.org/10.1016/j.freeradbiomed.2019.06.023openalex-snapshot
Pro-oxidant and pro-inflammatory effects of glycated albumin on cardiomyocytes
inferred← citeshttps://doi.org/10.1016/j.ijcard.2015.10.002openalex-snapshot
The importance of Pharmacovigilance for the drug safety: Focus on cardiovascular profile of incretin-based therapy
inferred← citeshttps://doi.org/10.1016/j.mam.2018.10.004openalex-snapshot
Diabesity and antidiabetic drugs
inferred← citeshttps://doi.org/10.1016/j.phrs.2020.105018openalex-snapshot
The treament of hyperglycemia in acute ischemic stroke with incretin-based drugs
inferred← citeshttps://doi.org/10.1038/nrendo.2016.86openalex-snapshot
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.1080/17425255.2023.2288252openalex-snapshot
A systematic review on the clinical pharmacokinetics of vildagliptin in healthy and disease populations
inferred← citeshttps://doi.org/10.1097/md.0000000000012633openalex-snapshot
Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes
inferred← citeshttps://doi.org/10.1111/dom.12760openalex-snapshot
Management of type 2 diabetes: t he current situation and key opportunities to improve care in the UK
inferred← citeshttps://doi.org/10.1111/dom.13038openalex-snapshot
Long‐term safety and efficacy of canagliflozin as add‐on therapy to teneligliptin in J apanese patients with type 2 diabetes
inferred← citeshttps://doi.org/10.1111/dom.13147openalex-snapshot
Direct head‐to‐head comparison of glycaemic durability of dipeptidyl peptidase‐4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A meta‐analysis of long‐term randomized controlled trials
inferred← citeshttps://doi.org/10.1136/bmj.i610openalex-snapshot
Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
inferred← citeshttps://doi.org/10.1136/bmjopen-2014-005892openalex-snapshot
A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients
inferred← citeshttps://doi.org/10.1136/bmjopen-2017-017260openalex-snapshot
Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1155/2017/5164292openalex-snapshot
Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
inferred← citeshttps://doi.org/10.1186/s13098-016-0131-yopenalex-snapshot
Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial
inferred← citeshttps://doi.org/10.1186/s40360-025-01055-2openalex-snapshot
Association between daily dose of dipeptidyl peptidase-4 inhibitors and change in glycated hemoglobin in patients with type 2 diabetes: interpretation of mixed-effects machine-learning models using electronic medical records
inferred← citeshttps://doi.org/10.1186/s40842-026-00296-2openalex-snapshot
Progressive loss of glycemic control during chronic DPP-4 inhibitor therapy despite preserved β-cell function: a case report suggesting acquired incretin resistance
inferred← citeshttps://doi.org/10.1210/jc.2017-01838openalex-snapshot
Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus
inferred← citeshttps://doi.org/10.12793/tcp.2020.28.e4openalex-snapshot
Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor
inferred← citeshttps://doi.org/10.12968/pnur.2015.26.3.140openalex-snapshot
New pharmacological approaches to diabetes management
inferred← citeshttps://doi.org/10.12970/2308-8044.2021.09.03openalex-snapshot
Metabolic Aspects of Five Commonly Used Non-Insulin Anti-Hyperglycemic Medications in Type 2 Diabetes
inferred← citeshttps://doi.org/10.1371/journal.pone.0164827openalex-snapshot
A Systematic Review of Methods for Handling Missing Variance Data in Meta-Analyses of Interventions in Type 2 Diabetes Mellitus
inferred← citeshttps://doi.org/10.1371/journal.pone.0171753openalex-snapshot
Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
inferred← citeshttps://doi.org/10.1515/rjdnmd-2015-0038openalex-snapshot
New Therapeutic Approaches to Prevent or Delay Beta-Cell Failure in Diabetes
inferred← citeshttps://doi.org/10.1517/14656566.2015.978289openalex-snapshot
A review of gliptins for 2014
inferred← citeshttps://doi.org/10.15406/ijmboa.2019.04.00119openalex-snapshot
Oral magnesium supplementation modulates hepatic and intestinal expression of some carbohydrate metabolizing genes in type 2 diabetic rats
inferred← citeshttps://doi.org/10.15406/ijmboa.4.6openalex-snapshot
inferred← citeshttps://doi.org/10.1586/14779072.2015.1046840openalex-snapshot
Sitagliptin for Type 2 diabetes: a 2015 update
inferred← citeshttps://doi.org/10.17925/ee.2019.15.2.67openalex-snapshot
Defining Disease Progression and Drug Durability in Type 2 Diabetes Mellitus
inferred← citeshttps://doi.org/10.18203/2320-6012.ijrms20214733openalex-snapshot
Indian consensus on durability of glycemic control in type 2 diabetes management and role of oral antidiabetic drugs
inferred← citeshttps://doi.org/10.2147/dmso.s202024openalex-snapshot
Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
inferred← citeshttps://doi.org/10.2147/vhrm.s68564openalex-snapshot
Alogliptin benzoate for management of type 2 diabetes
inferred← citeshttps://doi.org/10.2174/1573399817666201228120725openalex-snapshot
Pharmacological Management of Diabetes for Reducing Glucose Levels and Cardiovascular Disease Risk: What Evidence in South Asians?
inferred← citeshttps://doi.org/10.2337/db14-1706openalex-snapshot
Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism
inferred← citeshttps://doi.org/10.2337/dc17-1827openalex-snapshot
Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy
inferred← citeshttps://doi.org/10.2337/dci18-0033openalex-snapshot
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
inferred← citeshttps://doi.org/10.3389/fphar.2019.00576openalex-snapshot
Post-marketing Study of Linagliptin: A Pilot Study
inferred← citeshttps://doi.org/10.3390/biomedicines10051168openalex-snapshot
Inflammatory Mechanisms of Diabetes and Its Vascular Complications
inferred← citeshttps://doi.org/10.3390/ijerph16152720openalex-snapshot
The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect
inferred← citeshttps://doi.org/10.33978/2307-3586-2020-16-25-24-48openalex-snapshot
Clinical Pharmacology of Dipeptidyl Peptidase 4 Inhibitors: Comparative Review
inferred← citeshttps://doi.org/10.3904/kjim.2017.298openalex-snapshot
Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
inferred← citeshttps://doi.org/10.4093/dmj.2016.40.2.99openalex-snapshot
An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass
inferred← citeshttps://doi.org/10.4093/dmj.2017.41.5.337openalex-snapshot
Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
inferred← citeshttps://doi.org/10.4103/ijem.ijem_322_17openalex-snapshot
Sulfonylureas: Scoring beyond START STUDY
inferred← citeshttps://doi.org/10.4103/ijem.ijem_664_19openalex-snapshot
Surfing the vildagliptin tsunami
inferred← citeshttps://doi.org/10.48175/ijarsct-29254openalex-snapshot
Teneligliptin in Type 2 Diabetes Mellitus: A Comprehensive Review
inferred← citeshttps://doi.org/10.65540/jar.v30i.1595openalex-snapshot
Adapting Global Diabetes Management Guidelines for Low Resource Settings
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.